このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Bonesupport Holding マネジメント

マネジメント基準チェック /44

Bonesupport Holding'sの CEO はEmil Billbäckで、 Mar2018年に任命され、の在任期間は 6.25年です。の年間総報酬はSEK 15.18Mで、 41.7%給与と58.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.69%を直接所有しており、その価値はSEK 112.24M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と7.4年です。

主要情報

Emil Billbäck

最高経営責任者

SEK 15.2m

報酬総額

CEO給与比率	41.7%
CEO在任期間	6.5yrs
CEOの所有権	0.6%
経営陣の平均在職期間	4.8yrs
取締役会の平均在任期間	7.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Bonesupport Holding の収益と比較して、Emil Billbäck の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	SEK 289m
Mar 31 2024	n/a	n/a	SEK 267m
Dec 31 2023	SEK 15m	SEK 6m	SEK 245m
Sep 30 2023	n/a	n/a	SEK 214m
Jun 30 2023	n/a	n/a	-SEK 30m
Mar 31 2023	n/a	n/a	-SEK 51m
Dec 31 2022	SEK 18m	SEK 5m	-SEK 68m
Sep 30 2022	n/a	n/a	-SEK 72m
Jun 30 2022	n/a	n/a	-SEK 71m
Mar 31 2022	n/a	n/a	-SEK 82m
Dec 31 2021	SEK 6m	SEK 4m	-SEK 86m
Sep 30 2021	n/a	n/a	-SEK 88m
Jun 30 2021	n/a	n/a	-SEK 96m
Mar 31 2021	n/a	n/a	-SEK 92m
Dec 31 2020	SEK 11m	SEK 6m	-SEK 101m
Sep 30 2020	n/a	n/a	-SEK 115m
Jun 30 2020	n/a	n/a	-SEK 127m
Mar 31 2020	n/a	n/a	-SEK 151m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 161m
Sep 30 2019	n/a	n/a	-SEK 166m
Jun 30 2019	n/a	n/a	-SEK 191m
Mar 31 2019	n/a	n/a	-SEK 182m
Dec 31 2018	SEK 6m	SEK 4m	-SEK 176m

報酬と市場: Emilの総報酬 ($USD 1.49M ) は、 UK市場 ($USD 2.15M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Emilの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Emil Billbäck (54 yo)

6.5yrs

在職期間

SEK 15,176,000

報酬

Mr. Emil Billbäck serves as Director of Intervacc AB (publ) since May 15, 2024. He has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executiv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Emil Billbäck	Chief Executive Officer	6.5yrs	SEK 15.18m	0.60% SEK 117.4m
Håkan Johansson	Chief Financial Officer	5.8yrs	SEK 248.00k	0.084% SEK 16.5m
Michael Mortensen	Executive Vice President of Global R&D and Operations	2.8yrs	データなし	0% SEK 0
Annelie Vikner	Executive Vice President of Global Marketing	1.7yrs	データなし	0.022% SEK 4.3m
Helena Brandt	Executive Vice President of Human Resources	6.9yrs	データなし	0.015% SEK 3.0m
Michael Diefenbeck	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	7.4yrs	データなし	0.13% SEK 25.0m
Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	4.8yrs	データなし	0.036% SEK 7.2m
Michael Roth	GM & Executive VP of Commercial Operations of North America	4.3yrs	データなし	0.030% SEK 6.0m
Anna Stegmark	Executive Vice President of Quality Management & Regulatory Affairs	less than a year	データなし	データなし

4.8yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: BONEXSの経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Björn Odlander	Director	14.7yrs	SEK 302.00k	データなし
Lennart Johansson	Independent Chairman of the Board	7.7yrs	SEK 2.94m	0.25% SEK 50.1m
Sven Bjorklund	Independent Director	7.8yrs	SEK 253.00k	データなし
Christine Rankin	Independent Director	2.3yrs	SEK 756.00k	0.0036% SEK 700.2k
Mary O'Connor	Independent Director	2.3yrs	SEK 515.00k	0.039% SEK 7.7m

7.7yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: BONEXSの取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

Bonesupport Holding マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Insider recently bought kr426k worth of stock

Insider recently sold kr701k worth of stock

Chief Executive Officer recently sold kr15m worth of stock

No independent directors

Recent updates

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

Forecast breakeven date moved forward to 2023

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

No independent directors

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

No independent directors

No independent directors

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

No independent directors

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

No independent directors

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

No independent directors

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Less than half of directors are independent

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2021 earnings released

Forecast to breakeven in 2023

Less than half of directors are independent

Bonesupport Announces Supplementary US Denovo Application Submitted

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Less than half of directors are independent

Executive VP of R&D recently sold kr595k worth of stock

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr210k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Bonesupport Holding AB (publ) Receives Notification from the US Food and Drug Administration

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Revenue beats expectations

Executive VP of R&D recently bought kr69k worth of stock

Executive VP of R&D recently bought kr69k worth of stock

New 90-day high: kr77.00

New 90-day high: kr75.60

Bonesupport Holding AB (Publ) Announces Resignation of Simon Cartmell from the Board of Directors

Bonesupport Holding AB (publ) to Report First Half, 2021 Results on Jul 15, 2021

CEO報酬分析

CEO（最高経営責任者

マネジメント基準チェック /44